NEW YORK, NY / ACCESSWIRE / June 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Verastem, Inc. (NASDAQ: VSTM), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients.

The company recently announced the acceptance of its duvelisib New Drug Application by the U.S. Food and Drug Administration, with a Priority Review date later this year.

VSTM shares have moved upward over 50% in the past few trading sessions.

Duvelisib, FDA review, analysts' report and candidate pipeline available here READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/vstm/

The company recently made one oral and three poster presentations at the 23rd Congress of the European Hematology Association. The data presented at EHA this year continue to provide extremely important insights to guide the future clinical development of duvelisib across a wide range of hematologic malignancies, both as a monotherapy and in combination with other agents.

On June 14th, the company announced a registered sale of 7,166,666 shares of the Company's common stock at a price of $6.00 per share. The gross proceeds to Verastem Oncology from the offering are expected to be approximately $43.0 million.

Details of the new duvelisib data, pipeline review and Q1 financial data READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/vstm/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source